12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xalkori crizotinib regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending against the use of Xalkori crizotinib from Pfizer to treat previously treated, anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). The committee estimated...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >